Jpmorgan Chase & CO Celldex Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

  • $1.27 Trillion
  • Q1 2025

A detailed history of Jpmorgan Chase & CO transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 241,354 shares of CLDX stock, worth $4.82 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
241,354
Previous 85,545 182.14%
Holding current value
$4.82 Million
Previous $2.16 Million 102.68%
% of portfolio
0.0%
Previous 0.0%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 12, 2025
BUY
$18.15 - $27.6 $2.83 Million - $4.3 Million
155,809 Added 182.14%
241,354 $4.38 Million
Q4 2024

Feb 12, 2025
BUY
$23.31 - $32.4 $808,157 - $1.12 Million
34,670 Added 68.15%
85,545 $2.16 Million
Q3 2024

Dec 26, 2024
SELL
$32.06 - $44.56 $175,977 - $244,589
-5,489 Reduced 9.74%
50,875 $1.73 Million
Q3 2024

Nov 08, 2024
SELL
$32.06 - $44.56 $175,977 - $244,589
-5,489 Reduced 9.74%
50,875 $1.73 Million
Q2 2024

Dec 26, 2024
BUY
$32.76 - $42.56 $179,819 - $233,611
5,489 Added 10.79%
56,364 $2.09 Million
Q2 2024

Aug 12, 2024
BUY
$32.76 - $42.56 $314,790 - $408,959
9,609 Added 20.55%
56,364 $2.09 Million
Q1 2024

Dec 26, 2024
SELL
$35.22 - $51.88 $145,106 - $213,745
-4,120 Reduced 8.1%
46,755 $1.96 Million
Q1 2024

May 10, 2024
SELL
$35.22 - $51.88 $1.01 Million - $1.49 Million
-28,715 Reduced 38.05%
46,755 $1.96 Million
Q4 2023

Dec 26, 2024
BUY
$22.61 - $40.65 $556,092 - $999,786
24,595 Added 48.34%
75,470 $2.99 Million
Q4 2023

Feb 12, 2024
BUY
$22.61 - $40.65 $289,249 - $520,035
12,793 Added 20.41%
75,470 $2.99 Million
Q3 2023

Nov 14, 2023
SELL
$25.45 - $37.46 $945,365 - $1.39 Million
-37,146 Reduced 37.21%
62,677 $1.72 Million
Q2 2023

Aug 11, 2023
BUY
$30.29 - $38.28 $854,480 - $1.08 Million
28,210 Added 39.39%
99,823 $3.39 Million
Q1 2023

May 18, 2023
BUY
$34.78 - $47.43 $2.02 Million - $2.76 Million
58,174 Added 432.87%
71,613 $2.58 Million
Q1 2023

May 11, 2023
SELL
$34.78 - $47.43 $1.2 Million - $1.64 Million
-34,616 Reduced 72.03%
13,439 $483,000
Q4 2022

Feb 13, 2023
BUY
$27.78 - $45.38 $143,233 - $233,979
5,156 Added 12.02%
48,055 $2.14 Million
Q3 2022

Nov 14, 2022
BUY
$22.7 - $37.57 $12,553 - $20,776
553 Added 1.31%
42,899 $1.21 Million
Q2 2022

Aug 11, 2022
BUY
$20.5 - $37.33 $152,889 - $278,407
7,458 Added 21.38%
42,346 $1.14 Million
Q1 2022

May 11, 2022
SELL
$27.64 - $39.32 $2.57 Million - $3.65 Million
-92,946 Reduced 72.71%
34,888 $1.19 Million
Q4 2021

Feb 10, 2022
SELL
$35.68 - $56.27 $2.98 Million - $4.71 Million
-83,619 Reduced 39.54%
127,834 $4.94 Million
Q3 2021

Nov 12, 2021
BUY
$28.95 - $55.99 $6.12 Million - $11.8 Million
211,453 New
211,453 $11.4 Million

Others Institutions Holding CLDX

# of Institutions
188
Shares Held
69.3M
Call Options Held
220K
Put Options Held
310K
View Full List

About Celldex Therapeutics, Inc.

CLDX Quotes by TradingView
  • Ticker CLDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,772,400
  • Market Cap $933M
  • Description
  • Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...
More about CLDX
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email